Oleg Vishnevsky, MD
Interventional Cardiology · Philadelphia, PANPI 1700104957
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Shockwave Medical, Inc at 36.7% of the total.
Across 431 payments — averaging $112.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$18K
- Medtronic$8K
- Abbott$6K
- Boston Scientific$4K
- Abiomed$3K
- Angiodynamics, Inc.$3K
- plus $6K from 26 others
Across 2 payments — averaging $36,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Procyrion, Inc.$72K
What the payments were for
- Speaking & faculty fees$12,65026%
- Travel & lodging$14,16729%
- Food & beverage$21,76445%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 38 | $17,825 |
| Medtronic(2 entities) | 137 | $7,799 |
| Abbott | 80 | $6,217 |
| Boston Scientific | 25 | $3,973 |
| Abiomed | 42 | $3,409 |
| Angiodynamics, Inc. | 9 | $3,002 |
| Bayer | 12 | $1,857 |
| Edwards Lifesciences | 14 | $1,434 |
| Ancora Heart, Inc. | 7 | $921 |
| Amgen | 18 | $419 |
| Philips North America LLC | 13 | $256 |
| Asahi Intecc USA, Inc. | 1 | $219 |
| Livanova USA, Inc. | 2 | $168 |
| W. L. Gore & Associates, Inc. | 2 | $148 |
| Penumbra, Inc. | 1 | $125 |
| Siemens Medical Solutions USA, Inc. | 1 | $120 |
| Impulse Dynamics (USA) Inc. | 1 | $92 |
| AstraZeneca | 3 | $85 |
| Kiniksa Pharmaceuticals, Ltd. | 4 | $76 |
| Teleflex LLC | 2 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $60 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $58 |
| Endotronix, Inc. | 1 | $42 |
| Boehringer Ingelheim | 2 | $35 |
| Cardiovascular Systems Inc. | 2 | $33 |
| Heartflow, Inc. | 1 | $27 |
| Pfizer | 2 | $25 |
| Johnson & Johnson | 1 | $21 |
| KCI USA, Inc. | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Novartis | 1 | $14 |
| Merit Medical Systems Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$17,136
- AngioVac$2,952
- COREVALVE EVOLUT R$2,509
- Impella$2,381
- GENERAL - THERAPIES$1,391
- CoreValve Evolut$1,172
- NAVITOR$1,171
- Xience V coronary stent system$1,037
- Watchman$1,031
- SYMPLICITY G3$964
- TRICLIP$923
- AccuCinch$666
- AVVIGO Guidance System$565
- CARDIOMEMS$493
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$356
- SAPIEN 3 Ultra RESILIA$276
- Asahi Peripheral Vascular Wires$219
- PASCAL$214
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$207
- GENERAL VASCULAR ACCESS$168
How this compares
$48,581 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 35 | $31,188 |
| EliquisApixaban | 25 | $14,491 |
| JardianceEmpagliflozin | 11 | $5,945 |
| Icosapent Ethyl | 15 | $2,420 |
| Metoprolol Succinate | 31 | $1,041 |
| Atorvastatin Calcium | 46 | $1,029 |
| Losartan Potassium | 36 | $363 |
| Warfarin Sodium | 11 | $302 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 14 | $301 |
| ClopidogrelClopidogrel Bisulfate | 13 | $269 |
| Nifedipine ErNifedipine | 17 | $192 |
| Furosemide | 14 | $111 |
| Amiodarone Hcl | 15 | $92 |
| Lisinopril | 12 | $79 |
| Carvedilol | 16 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $14 | $31,18835 claims |
| PfizerEliquis | $25 | $14,49125 claims |
| Boehringer IngelheimJardiance | $35 | $5,94511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Philadelphia
- Jon GeorgePhiladelphia$637K
- Sanjog KalraPhiladelphia$444K
- Taisei KobayashiPhiladelphia$384K
- Howard HerrmannPhiladelphia$259K
- Jay GiriPhiladelphia$157K
- Paul FiorilliPhiladelphia$104K
- Nicholas RuggieroPhiladelphia$74K
- Craig FrankilPhiladelphia$59K
- Michael BodePhiladelphia$58K
- Ashwin NathanPhiladelphia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.